Zebrafish Lung Cancer Models

Background Models Details Phenotypic Evaluation Key Applications Study Examples

Background

Lung cancer is one of the leading causes of cancer-related mortality worldwide. It is broadly classified into non-small cell lung cancer (NSCLC), which accounts for approximately 85% of cases, and small cell lung cancer (SCLC), a highly aggressive neuroendocrine subtype. Major pathological features include uncontrolled epithelial cell proliferation, local invasion, angiogenesis, immune evasion, and frequent metastatic spread to the brain, bone, liver, and adrenal glands. Common clinical manifestations include persistent cough, dyspnea, chest pain, hemoptysis, weight loss, fatigue, and symptoms related to metastatic disease. Lung cancer primarily affects adults and older populations, with smoking, environmental exposure, and genetic alterations contributing to disease risk.

Current treatments include surgery, radiotherapy, platinum-based chemotherapy, targeted therapies against EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, and KRAS alterations, as well as immune checkpoint inhibitors. Despite major advances, many patients develop recurrence, metastasis, drug resistance, or limited response to immunotherapy. Conventional in vitro assays often fail to capture tumor dissemination, angiogenesis, and host-level toxicity. Zebrafish lung cancer models provide a rapid in vivo platform for evaluating tumor growth, invasion, metastasis, angiogenesis, and drug response using fluorescent imaging in live animals.

Why Zebrafish?

Transparent larvae enable real-time visualization of tumor growth and dissemination.
Small size supports rapid in vivo drug efficacy and toxicity screening.
Vascular reporter lines allow direct assessment of tumor-induced angiogenesis.
Patient-derived samples can be evaluated with short turnaround time.

Available Zebrafish Disease Models

Validated zebrafish lung cancer models integrate cell-line xenografts, patient-derived xenografts, metastasis-focused implants, and vascular reporter systems to study NSCLC/SCLC growth, brain metastasis, and anti-angiogenic response.

Model Name	Induction Method	Features
Lung Cancer Cell Line Xenograft Model	Fluorescently labeled human lung cancer cell lines, such as A549, H1299, H1975, HCC827, PC9, or H460 cells, are transplanted into zebrafish embryos or larvae.	A practical model for assessing tumor cell survival, proliferation, invasion, dissemination, and drug response. Suitable for early efficacy screening of chemotherapy, targeted agents, and combination treatments.
Patient-Derived NSCLC Xenograft Model	Fresh tumor cells, tumor fragments, or short-term cultured patient-derived NSCLC samples are implanted into zebrafish larvae.	Provides a patient-relevant platform for evaluating heterogeneous tumor behavior and short-term treatment response. Useful for translational research and personalized drug sensitivity studies.
Lung Cancer Brain Metastasis Model	Fluorescent NSCLC cells with brain-metastatic potential are injected into zebrafish larvae and monitored for dissemination to the brain region.	Supports investigation of tumor cell extravasation, brain colonization, blood–brain barrier-associated drug response, and anti-metastatic therapy evaluation.
Lung Cancer Angiogenesis Xenograft Model	Lung cancer cells are implanted into vascular reporter zebrafish lines, such as Tg(fli1:EGFP) or Tg(kdrl:EGFP), followed by live imaging of vessel response.	Enables quantification of tumor-induced angiogenesis, vessel recruitment, and anti-angiogenic drug activity. Suitable for VEGF/VEGFR pathway inhibitor studies and toxicity comparison.

Phenotypic Evaluation & Validation Assays

Drug Response and Safety

Reduction in tumor burden
Inhibition of invasion or angiogenesis
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Invasion and Metastasis

Migration distance from implantation site
Number of disseminated tumor foci
Brain-region colonization in metastasis models

Angiogenesis

Tumor-induced vessel sprouting
Peritumoral vessel density
Inhibition of vascular response after treatment

Tumor Growth

Tumor fluorescence area or intensity
Tumor expansion over time
Tumor growth inhibition after treatment

Key Applications

In vivo lung cancer drug screening for chemotherapy, targeted therapy, and combination regimens.
Evaluation of EGFR-, ALK-, KRAS-, MET-, and VEGF/VEGFR-directed agents in relevant xenograft settings.
Assessment of tumor invasion and metastatic dissemination, including brain metastasis-related studies.
Anti-angiogenic drug evaluation using vascular reporter zebrafish lines.
Patient-derived tumor response profiling to support translational oncology and personalized medicine research.

Study Examples

This study used a zebrafish tumor xenograft platform to implant patient-derived NSCLC samples and evaluate tumor behavior within a short assay window. The model assessed tumor invasiveness, dissemination, and treatment response in zebrafish larvae.

Fig. 1. Patient-derived NSCLC xenografts in zebrafish reproduce tumor dissemination patterns associated with clinical disease behavior (Ali Z, Vildevall M, et al., 2022).

The authors used transgenic vascular reporter zebrafish and human lung cancer xenografts to compare anti-angiogenic agents, including bevacizumab, endostar, and apatinib. Lung cancer cells were implanted into zebrafish embryos, and drug effects were evaluated through tumor-associated vascular changes, tumor growth, and toxicity-related phenotypes.

Fig. 2. Vascular reporter zebrafish enable comparison of anti-angiogenic efficacy and toxicity in lung cancer xenografts (Jin Y, Wei L, et al., 2018).

Accelerate Lung Cancer Research with Zebrafish Models

Accelerate lung cancer research with zebrafish models designed for rapid in vivo tumor growth analysis, metastasis assessment, angiogenesis evaluation, and drug response profiling.

Contact Our Scientists

References

Ali Z, Vildevall M, et al. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 2022;41(1):58.
Jin Y, Wei L, et al. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograft zebrafish model. Scientific Reports. 2018;8:15837.

For research use only. Not intended for any clinical use.